Last reviewed · How we verify
GSK1014802
At a glance
| Generic name | GSK1014802 |
|---|---|
| Also known as | BIIB074 and CNV1014802 |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. (PHASE1)
- Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects (PHASE1)
- Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1014802 CI brief — competitive landscape report
- GSK1014802 updates RSS · CI watch RSS
- Biogen portfolio CI